Paige Britt

The COMPETE trial reveals ITM-11 significantly improves progression-free survival and overall response rates in GEP-NET patients compared with everolimus.

Durvalumab enhances disease-free survival in high-risk non-muscle invasive bladder cancer when combined with BCG therapy, according to recent trial results.

A new study shows mRNA-4359 combined with pembrolizumab offers promising results for melanoma patients resistant to prior therapies.

Tagraxofusp shows manageable safety but limited efficacy in chronic myelomonocytic leukemia (CMML), with ongoing studies exploring combination therapies for better outcomes.

Tucatinib enhances progression-free survival (PFS) in HER2+ metastatic breast cancer, showcasing promising results in a pivotal phase 3 trial.

Xevinapant fails to enhance event-free survival (EFS) in head and neck cancer patients, revealing safety concerns and detrimental effects in treatment outcomes.

New dosimetry data highlights the safety and efficacy of ITM-11 for treating patients with gastroenteropancreatic neuroendocrine tumors, promising improved outcomes.

Recent analysis reveals that rectal spacers significantly lower recurrence rates in prostate cancer patients undergoing radiation therapy, enhancing treatment outcomes.

A clinical study highlights the safety and feasibility of ClearPoint Prism Neuro Laser Therapy for treating brain tumors, showcasing innovative minimally invasive techniques.

A phase 2 trial reveals that ONO-4578 and nivolumab significantly extend progression-free survival in advanced gastric cancer patients.

A phase 2 trial reveals PSMA-PET–guided salvage radiotherapy significantly enhances cancer control in patients with prostate cancer post surgery.

A recent study reveals that systematic mediastinal lymph node dissection is unnecessary for stage T1 GGO-dominant lung adenocarcinoma, enhancing patient outcomes.

A new study reveals casdatifan's promising efficacy in treating late-stage kidney cancer, showing significant progression-free survival and response rates.

Ziftomenib shows promising results in treating relapsed/refractory acute myeloid leukemia with NPM1 mutations, offering hope for improved patient outcomes.

FDA designates AMXT 1501 and DFMO as an orphan drug for neuroblastoma, aiming to enhance treatment outcomes for pediatric patients.

Innovative DNA-based immunotherapy shows promise, achieving over five years of recurrence-free survival in patients with aggressive brain and liver cancers.